Promega

#3D cell culture #Assays #Organoids #Promega

From monolayer to microtissue: Measuring what matters in 3D drug discovery

Darren Heywood, Senior Product Manager at Promega UK, examines assay formats built specifically for 3D measurements. A 3D microtissue, such as a spheroid or organoid, is not a monolayer with more cells. These are three-dimensional cultures that self-organise into structures resembling real tissue. In a spheroid, as it grows, oxygen and… Read More

#Exclusive Content

#Assays #Drug screening #In vivo #Promega

Five questions to answer before you move your assays from 2D to 3D 

This paid-for advertorial by Promega appeared in DDW Volume 27 – Issue 3, Summer 2026.   The shift from 2D monolayers to 3D cell culture models like spheroids, organoids, and complex tissue constructs, is gaining momentum in the drug discovery space. And for good reason: 3D models better recapitulate in vivo biology, improving the predictive value of early… Read More

#Exclusive Content

#AI #Charles River #Emulate #Lab automation #Promega #SLAS2026

SLAS2026: Day Two Round-Up

DDW covers some of the biggest announcements from the second day of SLAS2026.     Emulate showcases organ-chip platform at SLAS2026   Emulate has brought its AVA Emulation System to SLAS2026, showcasing the potential to accelerate drug development with a first-of-its-kind high-throughput organ-chip platform. Read more…   Charles River and… Read More

#News

amino acids chain
#Cellular assays #Promega #SLAS2026

Promega launches cellular target engagement platform 

Promega has launched a new live-cell target engagement platform aiming to close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins.  TheTarSeer BRETSA Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. … Read More

#News

#Drug discovery #Drug screening #Merck #Promega

Merck and Promega to co-develop drug discovery technologies 

Merck has entered a partnership with global life science service Promega Corporation to co-develop technologies advancing drug screening and discovery.  The agreement will bring together Merck’s expertise in organoids and synthetic chemistry with Promega's assay and reporter technologies. The companies aim to develop assays capable of tracking cellular activity in… Read More

#Business & Investment #News

#mRNA #mRNA-based vaccines #Promega #Therapeutics

Bridge innovation to implementation with high-quality RNA therapeutic raw materials 

This article is sponsored by Promega. In today’s fast-paced RNA therapeutic development landscape, experience matters. With over 40 years of experience in RNA synthesis by in vitro transcription (IVT), Promega smooths the transition from research to production by reducing risk and saving time, without compromising the quality of RNA synthesis… Read More

#News